A Phase 1b/2a, Multicenter, Open-label Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Status: Recruiting
Location: See all (22) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY
The purpose of this study is to evaluate the preliminary safety and determine the RP2D of mezigdomide in combination with elranatamab in participants with relapsed and refractory multiple myeloma (RRMM).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Age ≥18 with history of relapsed and refractory multiple myeloma (RRMM) treated with 2 to 4 prior lines of anti-myeloma therapy (Phase 1) or 1 to 3 prior lines of anti-myeloma therapy (Phase 2).
• Measurable MM by local laboratory.
• Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1.
• Adherence to contraception requirements.
Locations
United States
Alabama
Local Institution - 0001
NOT_YET_RECRUITING
Birmingham
Connecticut
Local Institution - 0029
NOT_YET_RECRUITING
New Haven
New Jersey
Local Institution - 0028
NOT_YET_RECRUITING
Hackensack
Texas
University of Texas MD Anderson Cancer Center
RECRUITING
Houston
Other Locations
Canada
Local Institution - 0032
NOT_YET_RECRUITING
Calgary
Local Institution - 0027
NOT_YET_RECRUITING
Halifax
Princess Margaret Cancer Centre
RECRUITING
Toronto
Local Institution - 0026
NOT_YET_RECRUITING
Vancouver
China
Local Institution - 0031
NOT_YET_RECRUITING
Shanghai
Local Institution - 0030
NOT_YET_RECRUITING
Suzhou
Germany
Local Institution - 0015
NOT_YET_RECRUITING
Dresden
Local Institution - 0013
NOT_YET_RECRUITING
Hamburg
Local Institution - 0014
NOT_YET_RECRUITING
Heidelberg
Greece
Local Institution - 0011
NOT_YET_RECRUITING
Athens
Local Institution - 0012
NOT_YET_RECRUITING
Athens
Norway
Local Institution - 0019
NOT_YET_RECRUITING
Oslo
Local Institution - 0017
NOT_YET_RECRUITING
Trondheim
Spain
Local Institution - 0022
NOT_YET_RECRUITING
Salamanca
Local Institution - 0021
NOT_YET_RECRUITING
Santander
United Kingdom
Local Institution - 0016
NOT_YET_RECRUITING
London
Local Institution - 0018
NOT_YET_RECRUITING
London
Local Institution - 0020
NOT_YET_RECRUITING
Manchester
Contact Information
Primary
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Clinical.Trials@bms.com
855-907-3286
Backup
First line of the email MUST contain the NCT# and Site #.
Time Frame
Start Date: 2025-10-07
Estimated Completion Date: 2027-06-03
Participants
Target number of participants: 62
Treatments
Experimental: Phase 1
Experimental: Phase 2
Related Therapeutic Areas
Sponsors
Leads: Celgene